BR100 Decreased By (-0.98%)
BR30 Decreased By (-0.58%)
KSE100 Decreased By (-0.97%)
KSE30 Decreased By (-1.07%)
AGHA 7.70 Decreased By ▼ -0.11 (-1.41%)
BECO 5.13 Decreased By ▼ -0.08 (-1.54%)
BML 56.67 Decreased By ▼ -0.83 (-1.44%)
BOP 33.75 Decreased By ▼ -0.28 (-0.82%)
CNERGY 9.88 Decreased By ▼ -0.08 (-0.8%)
CSIL 5.29 Decreased By ▼ -0.02 (-0.38%)
FCCL 53.09 Decreased By ▼ -1.61 (-2.94%)
FFL 16.52 Decreased By ▼ -0.17 (-1.02%)
FNEL 1.21 Decreased By ▼ -0.02 (-1.63%)
KEL 7.22 Decreased By ▼ -0.18 (-2.43%)
KOSM 5.72 Decreased By ▼ -0.05 (-0.87%)
LOTCHEM 29.31 Decreased By ▼ -0.01 (-0.03%)
MLCF 92.16 Decreased By ▼ -2.20 (-2.33%)
NBP 201.61 Decreased By ▼ -1.44 (-0.71%)
NCPL 56.45 Decreased By ▼ -0.55 (-0.96%)
NPL 66.57 Decreased By ▼ -1.13 (-1.67%)
OGDC 316.29 Increased By ▲ 0.45 (0.14%)
PACE 10.48 Decreased By ▼ -0.16 (-1.5%)
PAEL 42.04 Decreased By ▼ -1.16 (-2.69%)
PIBTL 16.41 Decreased By ▼ -0.33 (-1.97%)
PPL 216.84 Decreased By ▼ -2.94 (-1.34%)
PRL 50.86 Increased By ▲ 1.67 (3.39%)
PTC 69.86 Decreased By ▼ -0.67 (-0.95%)
SSGC 26.98 Decreased By ▼ -1.27 (-4.5%)
TBL 9.73 Decreased By ▼ -0.13 (-1.32%)
TELE 8.65 Decreased By ▼ -0.14 (-1.59%)
TPL 17.90 Decreased By ▼ -0.34 (-1.86%)
TPLP 13.39 Increased By ▲ 0.12 (0.9%)
TREET 22.56 Decreased By ▼ -0.16 (-0.7%)
TRG 59.26 Decreased By ▼ -0.88 (-1.46%)
World

UK health minister says data on Pfizer vaccine supports shift to 12-week dosing schedule

  • Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers.
Published Updated
By

LONDON: Data supports Britain's decision to move to a 12-week dosing schedule for Pfizer's COVID vaccine, health minister Matt Hancock said on Thursday, adding details on efficacy gathered during the rollout would be published as soon as possible.

"Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers, saying he had reviewed the data, and that it supported the decision to move to a 12-week schedule between doses.

"We're looking at this data, and in fact we're measuring the efficacy here at home for those who've been vaccinated, by matching the data between those who've been vaccinated and those who test positive. And we're monitoring that and we will publish that data as soon as it is clinically valid."

Comments

Comments are closed for this article.